Chong Kun Dang runs new global drug for treatment of dyslipidemia

As new clinical trial results of dyslipidemia treatment were recently revealed in the U.S., ‘CKD-519’ being developed by Chong Kun Dang has raised expectations.

CKD-519, a new dyslipidemia drug with a new mechanism that reduces low density lipoprotein(LDL) cholesterol and neutral fat that are harmful to human body and increases high density lipoprotein(HDL) cholesterol that is helpful to peopl...